アジア オオテメーカー ノ アセアン センリャク １ チュウゴク コウテツ （タイワン）

台湾最大の鉄鋼メーカー、中国鋼鉄（CSC）は内需が狭小なため、鉄鋼需要が急拡大しているASEAN（東南アジア諸国連合）市場に成長を託す。建材市場向けにはマレーシアで冷延工場を稼働させ、ベトナムでは台湾の化学最大手、台湾プラスチックなどと銑鋼一貫メーカー、フォルモサ・ハティン・スチール（FHS）を設立。2017年５月に同国初の高炉を稼働させ、ASEANでの一貫生産体制を確立した。台湾は日本、韓国と違ってASEANとの間でFTA（自由貿易協定）がないため、熱延鋼板など鉄源の現地生産で輸出関税を回避する。ベトナム国内にもつ新日鉄住金との合弁薄板工場にその母材となる熱延鋼板を供給、外販も始める。自動車、家電向けの高付加価値路線を目指すが、ASEAN鉄鋼需要の太宗はなお建材向けであり、実現は容易ではない

Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)

Introduction Given an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate the safety and efficacy profile of long-term usage of alogliptin.Research design and methods We registered 5969 patients from April 2012 through September 2014, who started receiving alogliptin (group A) or other classes of oral hypoglycemic agents (OHAs; group B), and were followed for 3 years at 239 sites nationwide. Safety was the primary outcome. Symptomatic hypoglycemia, pancreatitis, skin disorders of non-extrinsic origin, severe infections, and cancer were collected as major adverse events (AEs). Efficacy assessment was the secondary outcome and included changes in hemoglobin A1c (HbA1c), fasting blood glucose, fasting insulin and urinary albumin.Results Of the registered, 5150 (group A: 3395 and group B: 1755) and 5096 (3358 and 1738) were included for safety and efficacy analysis, respectively. Group A patients mostly (>90%) continued to use alogliptin. In group B, biguanides were the primary agents, while DPP-4 inhibitors were added in up to ~36% of patients. The overall incidence of AEs was similar between the two groups (42.7% vs 42.2%). Kaplan-Meier analysis revealed the incidence of cancer was significantly higher in group A than in group B (7.4% vs 4.8%, p=0.040), while no significant incidence difference was observed in the individual cancer. Multivariate Cox regression analysis revealed that the imbalanced patient distribution (more elderly patients in group A than in group B), but not alogliptin usage per se, contributed to cancer development. The incidence of other major AE categories was with no between-group difference. Between-group difference was not detected, either, in the incidence of microvascular and macrovascular complications. HbA1c and fasting glucose decreased significantly at the 0.5-year visit and nearly plateaued thereafter in both groups.Conclusions Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting